Doctor Ewelina Kulikowski
Resverlogix Corp., Calgary (Canada)
Apabetalone, a BET inhibitor, attenuates inflammation induced by viral RNA mimetic and reduces SARS-CoV-2 spike protein binding regardless of variants
Event: ESC Congress 2022
Topic: Pharmacotherapy
Session: Pericardial disease, myocardial disease, COVID-19
Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism
Event: ESC Congress 2019
Topic: Inflammation and Immunity
Session: Coronary artery disease inflammation
Apabetalone (RVX-208) Reduces Monocyte-Endothelial Cell Adhesion and Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and in Inflamed Mouse Aorta
Event: ESC Congress 2018
Topic: Genetics, Epigenetics, ncRNA
Session: Late Breaking Basic and Translational Science - Vascular Biology
Apabetalone (RVX-208) impacts key biomarkers and pathways associated with cardiovascular disease in patients with severe renal impairment
Event: ESC Congress 2017
Topic: CAD and comorbidities
Session: CAD and comorbidities
Modulation of the complement cascade in cardiovascular disease patients by a bromodomain and extraterminal (BET) protein inhibitor
Event: ESC Congress 2016
Topic: Inflammation and microcirculation
Session: Inflammation and immunity
ESC 365 is supported by
